AstraZeneca : Enhertu Shows Robust And Durable Tumor Response Of 54.9% In Patients With Lung Cancer
18/9 15:54
(RTTNews) - AstraZeneca Plc. (AZN, AZN.L) and Daiichi Sankyo's HER2-directed antibody drug conjugate, Enhertu, demonstrated robust and durable tumor response of 54.9% in previously treated patients with HER2-mutant or HER2m unresectable and/or metastatic non-squamous non-small ce...